Matthew Gline is CEO at Roivant Sciences Ltd. (ROIV). They have made 14 open-market trades across 1 company since 2022, most recently 2026-09-30.
CIK 0001750094
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $50K since 2025, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ROIV | 16,583,774 | $555.7M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ROIV | SELL | 2026-04-16 | 2026-04-20 | $29.16 | $8.4M | -1.7% | +11.6% | +17.4% |
| ROIV | SELL | 2025-12-15 | 2025-12-17 | $21.68 | $75.4M | -4.3% | +2.3% | +25.2% |
| ROIV | BUY | 2025-09-18 | 2025-09-18 | $15.07 | $50K | -0.3% | +16.9% | +49.5% |
| ROIV | SELL | 2024-09-23 | 2024-09-24 | $11.79 | $46.8M | -2.1% | +1.5% | +2.9% |
| ROIV | SELL | 2022-10-25 | 2022-10-27 | $4.40 | $170K | -2.0% | -1.2% | +64.5% |
| ROIV | SELL | 2022-09-23 | 2022-09-27 | $3.07 | $129K | +41.5% | +64.6% | +142.8% |
| ROIV | SELL | 2022-08-24 | 2022-08-26 | $3.71 | $148K | -5.1% | -24.2% | +32.6% |
| ROIV | SELL | 2022-07-25 | 2022-07-27 | $4.33 | $177K | -6.4% | -10.9% | +13.5% |
| ROIV | SELL | 2022-06-23 | 2022-06-27 | $4.34 | $172K | +3.6% | -10.3% | -36.8% |
| ROIV | SELL | 2022-05-20 | 2022-05-24 | $3.70 | $1.0M | +3.1% | +21.0% | -4.4% |
| ROIV | SELL · 10b5-1 | 2022-04-25 | 2022-04-27 | $3.84 | $33K | -15.7% | +7.7% | +10.9% |
| ROIV | SELL | 2022-03-30 | 2022-04-01 | $4.84 | $326K | -13.8% | -19.6% | -15.0% |
| ROIV | SELL | 2022-03-25 | 2022-03-29 | $5.06 | $358K | -14.4% | -20.4% | -3.5% |
| ROIV | SELL | 2022-03-18 | 2022-03-22 | $5.13 | $841K | -10.4% | -31.5% | -20.9% |
| ROIV | SELL | 2022-03-07 | 2022-03-09 | $5.52 | $1.0M | +7.4% | -21.0% | -20.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.